Better outcomes in severe COVID-19 patients administered interleukin-6 inhibitors early.

[2greys]

New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses. The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. Published in the International Journal of Infectious Diseases, the results show Interleukin-6 inhibitors appear to be a more effective treatment compared to other options, including remedesvir and dexamethasone, which are recommended and currently used in the pandemic.

bmc.org/news/press-releases...

International Journal Of Infectious Diseases

ijidonline.com/article/S120...

[Bkin]

I've mainly stopped reading stuff coming out of the US after finding out trump had shares in the vaccine for covid-19 promotion. Wouldn't touch any vaccine that man had shares in.

However IL-6 has its origins from Japanese research on Inflammation and Immunity Disease:

ncbi.nlm.nih.gov/pmc/articl...

So likely it would help in many different illnesses.